TdC 357: Análogos de GLP-1 na prática - 4 clinicagens
· 45 min · S8 E357
Episode TdC 357: Análogos de GLP-1 na prática - 4 clinicagens
Marcela Belleza e Ênio Macedo convidam novamente Nathalie Santana para debater clinicagens sobre o uso dos análogos do peptídeo semelhante ao glucagon 1 (GLP-1) na prática. O episódio inicia explicando qual o panorama atual das medicações no Brasil (quais fármacos são comercializados, quebra de patente, como usar as canetas), e partem para as 4 clinicagens:
- indicações além do tratamento da obesidade e do diabetes tipo 2 - eventos adversos novos - cuidados em cenários específicos (gestações, perioperatório, idosos) - estratégias para suspensão e redução de custo
Referências:
• ADA Professional Practice Committee for Obesity. Pharmacologic treatment of obesity in adults: Standards of Care in Overweight and Obesity. BMJ Open Diabetes Res Care. 2026. • Aronne LJ, et al. Orforglipron for maintenance of body weight reduction (ATTAIN-MAINTAIN). Nat Med. 2026. • Batsis JA, et al. Effect of incretin-based and nonpharmacologic weight loss on body composition: a systematic review. Ann Intern Med. 2026. • Bliddal H, et al. Once-weekly semaglutide in persons with obesity and knee osteoarthritis (STEP 9). N Engl J Med. 2024. • Bonaca MP, et al. Semaglutide and walking capacity in peripheral artery disease and type 2 diabetes (STRIDE). Lancet. 2025. • Celletti F, et al. WHO guideline on GLP-1 therapies for obesity in adults. JAMA. 2026. • Das SR, et al. 2020 ACC Expert Consensus Decision Pathway on novel therapies for cardiovascular risk reduction in type 2 diabetes. J Am Coll Cardiol. 2020. • Marino EC, et al. Perioperative hyperglycemia screening and control: SBD/SBA/ABESO joint position statement. Brazilian Diabetes Society Guideline. 2026. • He L, et al. GLP-1 receptor agonists and risk of gallbladder and biliary diseases: a meta-analysis. JAMA Intern Med. 2022. • Horn DB, et al. Tirzepatide for maintenance of bodyweight reduction (SURMOUNT-MAINTAIN). Lancet. 2026. • Malhotra A, et al. Tirzepatide for obstructive sleep apnea and obesity (SURMOUNT-OSA). N Engl J Med. 2024. • Nauck MA, et al. GLP-1 receptor agonists and next-generation incretin-based medications. Lancet. 2026. • Perkovic V, et al. Effects of semaglutide on chronic kidney disease in type 2 diabetes (FLOW). N Engl J Med. 2024. • Rosen CJ, Ingelfinger JR. GLP-1 receptor agonists. N Engl J Med. 2026. • Saraiva JFK, et al. 2025 Brazilian guideline on obesity management and cardiovascular prevention. Arq Bras Cardiol. 2025. • Sanyal AJ, et al. Semaglutide in metabolic dysfunction-associated steatohepatitis (ESSENCE). N Engl J Med. 2025. • Wyckoff JA, et al. Preexisting diabetes and pregnancy: Endocrine Society/ESE guideline. Eur J Endocrinol. 2025. • Brazilian Society of Anesthesiology (SBA). Update on perioperative management of GLP-1 RAs and GLP-1/GIP co-agonists. 2026. Available at: sbahq.org
Shows are listed from Apple Podcasts' charts and directory, and Podcast Index where it is used. Every show and episode belongs to its publisher and plays from the publisher's own feed; this site hosts none of them. Explicit shows are for adult profiles only, and children’s profiles hear only children’s shows. More about this list.